Mucosal melanoma following autologous stem cell transplantation for non-Hodgkin's lymphoma (NHL).
The incidence of secondary malignancy following autologous stem cell transplantation (ASCT) is increasing. We describe a patient with stage IVB Hodgkin's disease who developed primary amelanotic malignant melanoma of the tongue 18 months following autologous stem cell transplantation. She was treated by partial glossectomy and supra-omohyoid neck dissection followed by cytokine-mediated immunotherapy. Malignant melanoma of the skin is a frequent secondary solid tumor seen in patients undergoing stem cell transplantation. However, mucosal melanoma which is rare by itself (0.2-8%) has never been reported in NHL patients following ASCT. Early diagnosis and initiation of combined local and systemic treatments including immuno-therapy may improve the outcome of this rare but lethal complication.
Ben-Yosef
R
R
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Braverman
I
I
Saah
D
D
Nagler
R
R
Shohat
S
S
Or
R
R
Nagler
A
A
D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000473:pathology / Q000628:therapy*; D018328:Melanoma, Amelanotic / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D009062:Mouth Neoplasms / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D014182:Transplantation, Autologous